Vitamin D Metabolism and Deficiency

Vitamin D is a fat-soluble steroid hormone essential for calcium homeostasis, phosphate metabolism, and immune function, synthesized cutaneously from 7-dehydrocholesterol upon UVB exposure or obtained from dietary sources. Vitamin D deficiency has reached epidemic proportions worldwide, affecting an estimated 1 billion people globally with highest prevalence in northern latitudes, darker-skinned individuals in high-latitude regions, and those with limited sun exposure or malabsorption disorders. Clinical significance extends beyond skeletal manifestations to include increased susceptibility to infections, cardiovascular disease, autoimmune conditions, and malignancy, making it a crucial consideration across multiple organ systems. The condition is characterized by 25-hydroxyvitamin D [25(OH)D] concentrations <20 ng/mL (50 nmol/L), though optimal levels remain debated in the medical literature. For USMLE Step 2 CK, recognition of vitamin D deficiency presentations, understanding the two-step hydroxylation pathway, and knowledge of treatment strategies represent high-yield topics frequently tested in clinical vignettes involving bone disease, hypocalcemia, or patients with risk factors for deficiency.

Vitamin D metabolism involves a precisely orchestrated two-step hydroxylation process that converts inactive precursors into the biologically active hormone calcitriol, with dysregulation at any step resulting in clinical deficiency:

Vitamin D (cholecalciferol) from either cutaneous synthesis or dietary sources undergoes the first hydroxylation in hepatic mitochondria via the enzyme 25-hydroxylase (CYP2R1), producing 25-hydroxyvitamin D [25(OH)D], also termed calcifediol. This inactive circulating form represents the best indicator of total body vitamin D stores with a half-life of 2-3 weeks and serves as the substrate for downstream activation. The hepatic hydroxylation step is essentially unregulated and substrate-dependent; therefore, serum 25(OH)D concentration directly reflects vitamin D status. Measurement of 25(OH)D defines vitamin D deficiency, insufficiency, and sufficiency status for clinical decision-making. Chronic liver disease impairs this step, resulting in low 25(OH)D despite adequate vitamin D intake or synthesis.

The renal proximal tubular cells express 1α-hydroxylase (CYP27B1), which catalyzes conversion of 25(OH)D to 1,25-dihydroxyvitamin D [1,25(OH)₂D], the most biologically active form with 100-1000 times greater potency than the parent compound. Calcitriol [1,25(OH)₂D] has a much shorter half-life of 4-6 hours and exists in picomolar concentrations. Tight hormonal regulation of 1α-hydroxylase activity is critical: parathyroid hormone (PTH) upregulates the enzyme in response to hypocalcemia or hyperphosphatemia, while calcitriol itself provides negative feedback inhibition through induction of 24-hydroxylase. Fibroblast growth factor 23 (FGF23) suppresses 1α-hydroxylase activity while promoting catabolism via 24-hydroxylase, particularly in phosphate homeostasis. Consequently, patients with vitamin D deficiency may have relatively preserved 1,25(OH)₂D levels initially due to compensatory PTH-driven activation, explaining the phenomenon wherein symptomatic deficiency can exist with "normal" calcitriol levels—a critical concept for board examinations.

Both 25(OH)D and 1,25(OH)₂D undergo inactivation by renal and extrarenal 24-hydroxylase (CYP24A1), producing less active metabolites (24,25(OH)₂D and 1,24,25(OH)₃D) that are subsequently excreted. This catabolic pathway is activated by calcitriol itself and FGF23, creating a negative feedback loop that prevents excessive activation. Enhanced 24-hydroxylase activity in vitamin D deficiency (due to compensatory PTH stimulation) paradoxically accelerates catabolism of whatever 25(OH)D is available, worsening depletion.

Macrophages, dendritic cells, and activated lymphocytes express 1α-hydroxylase independent of renal control, allowing local calcitriol production in granulomatous diseases (sarcoidosis, tuberculosis, histoplasmosis, coccidioidomycosis), lymphomas, and chronic inflammatory conditions. This unregulated activation produces the hypercalcemia-hypercalciuria phenomenon observed in sarcoidosis and explains why patients with these conditions may develop hypercalcemia despite low 25(OH)D levels.

Calcitriol exerts effects through the vitamin D receptor (VDR), a nuclear receptor present in virtually all tissues. In the intestine, calcitriol binding to VDR increases expression of calcium-binding protein (calbindin D28K), alkaline phosphatase, and the apical calcium channel TRPV6, enhancing fractional calcium absorption from 10-15% to 30-40%. In bone, calcitriol promotes both osteoblast differentiation and osteoclast activation through RANKL upregulation; the net effect depends on PTH status and calcium availability. In the parathyroid gland, calcitriol directly suppresses PTH synthesis and secretion, completing the negative feedback loop. Systemic effects include enhanced phosphate reabsorption in the renal proximal tubule and modulation of immune cell function through VDR-mediated effects on T-cell differentiation and antimicrobial peptide production.

When 25(OH)D falls below ~30 ng/mL, renal calcitriol production becomes insufficient to maintain serum calcium despite maximized intestinal calcium absorption. The resulting hypocalcemia (or even subtle decreases detected by calcium-sensing receptor on parathyroid chief cells) triggers PTH secretion. PTH restores serum calcium through three mechanisms: (1) enhanced renal tubular calcium reabsorption, (2) stimulation of renal 1α-hydroxylase to increase calcitriol production, and (3) increased bone resorption via osteoclast activation. However, chronic PTH excess causes high-turnover bone disease, increased bone resorption exceeding formation, and paradoxically increased fracture risk despite elevated PTH. The elevated PTH also stimulates FGF23 secretion from osteoblasts, which independently suppresses 1α-hydroxylase and promotes phosphaturia, leading to renal phosphate wasting and hypophosphatemia. This complex endocrine adaptation eventually becomes maladaptive, driving osteomalacia and secondary hyperparathyroid bone disease.

Vitamin D deficiency results from reduced synthesis, inadequate intake, impaired activation, or increased catabolism. Understanding the mechanism in each patient guides targeted therapy:

Reduced UVB exposure due to geographic latitude >35°, winter season (sun angle too oblique for adequate UVB penetration), indoor occupation, religious or cultural clothing practices, and routine use of sunscreen or protective clothing. Darker skin pigmentation increases melanin content, which reduces UVB penetration and cutaneous vitamin D synthesis by 3-6 fold compared to fair-skinned individuals—a critical factor explaining higher deficiency prevalence in African Americans and other individuals with darker phenotypes living in northern climates. Aging skin (>65 years) also produces 25-50% less vitamin D per unit UVB exposure due to reduced 7-dehydrocholesterol content.

Vitamin D is naturally present in fatty fish (salmon, mackerel, herring: 600-1000 IU/100g), fish liver oils, egg yolks (40-60 IU per egg), mushrooms exposed to UVB light, and fortified dairy products and cereals (typically 100-400 IU per serving). Strict vegan or vegetarian diets, avoidance of fortified foods, and limited consumption of fatty fish dramatically increase risk. Infants exclusively breastfed without supplementation are particularly vulnerable, as human breast milk contains minimal vitamin D (25-78 IU/L) regardless of maternal status.

Conditions affecting fat absorption impair vitamin D absorption, as the vitamin is fat-soluble and requires micelle formation for intestinal uptake. Celiac disease, inflammatory bowel disease (Crohn's disease > ulcerative colitis), cystic fibrosis, chronic pancreatitis, short bowel syndrome, and post-bariatric surgery patients demonstrate profoundly low 25(OH)D levels. Cholestasis and severe hepatic dysfunction impair both vitamin D absorption and hepatic 25-hydroxylation, creating dual defects.

Glomerular filtration rate decline reduces renal mass available for 1α-hydroxylase activity, directly impairing calcitriol synthesis. Additionally, CKD causes hyperphosphatemia, which suppresses 1α-hydroxylase and stimulates FGF23, further reducing activation. Patients with stage 3-5 CKD frequently exhibit both low 25(OH)D (due to reduced intake/synthesis) and inappropriately low or normal 1,25(OH)₂D (due to impaired renal activation), creating a "functional deficiency" state distinct from nutritional deficiency.

Cirrhosis impairs both the 25-hydroxylation step and 1,25(OH)₂D catabolism simultaneously, though usually the former predominates. Patients demonstrate profoundly low 25(OH)D and normal or elevated 1,25(OH)₂D levels due to reduced catabolism. Cholestasis compounds the problem through impaired fat absorption.

Anticonvulsants (phenytoin, phenobarbital, carbamazepine) and rifampicin induce hepatic and renal CYP450 enzymes, including CYP24A1, thereby accelerating calcitriol catabolism and reducing 1,25(OH)₂D levels. Chronic corticosteroid use impairs intestinal calcium absorption and reduces 1α-hydroxylase activity, while also promoting bone loss through direct osteoblast inhibition. Antifungal agents (azoles), antiretrovirals, and some anticonvulsants can impair 1α-hydroxylase activity directly.

Sarcoidosis, tuberculosis, coccidioidomycosis, histoplasmosis, and berylliosis cause activated macrophages to express 1α-hydroxylase independent of renal regulation, producing uncontrolled calcitriol synthesis and resulting in hypercalcemia despite low 25(OH)D. Lymphomas, particularly Hodgkin's and non-Hodgkin's types, similarly express 1α-hydroxylase activity in involved tissues. These conditions represent a distinct pathophysiologic mechanism and must be excluded in patients presenting with hypercalcemia and elevated 1,25(OH)₂D.

Vitamin D-dependent rickets type 1 (VDDR1) results from homozygous or compound heterozygous loss-of-function mutations in CYP27B1 (1α-hydroxylase gene), causing severe impairment of calcitriol synthesis despite adequate 25(OH)D and elevated PTH. VDDR type 2 involves VDR gene mutations causing end-organ resistance to calcitriol, with extremely elevated 1,25(OH)₂D levels despite clinical features of deficiency. Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) results from inactivating FGF23 mutations, causing excessive 1α-hydroxylase activity and calcitriol overproduction. These conditions are rare but high-yield for USMLE boards.

Multifactorial reduction in vitamin D status with age includes reduced sun exposure, decreased dietary intake, impaired cutaneous synthesis, reduced intestinal calcium absorption even at higher calcitriol levels, and declining renal function. Elderly patients require particular vigilance and supplementation.

The clinical manifestations of vitamin D deficiency span a wide spectrum from asymptomatic biochemical abnormality to severe symptomatic disease, with presentation heavily dependent on severity, acuity of development, and concurrent calcium and phosphate status:

Patients with moderate-to-severe deficiency frequently report diffuse, nonspecific musculoskeletal pain affecting proximal muscles (hip, shoulder girdles), lower back, and lower extremities. Pain is often described as aching, burning, or tender to palpation and may worsen with weight-bearing activities. The pathophysiology involves altered calcium and phosphate metabolism impairing muscle contractility and energy metabolism, direct VDR-mediated effects on skeletal muscle mitochondrial function and calcium handling, and possible sarcopenia from reduced protein synthesis. Proximal muscle weakness accompanies pain in severe deficiency, manifesting as difficulty rising from a seated position, climbing stairs, or lifting objects—distinguishing muscular rather than neurologic origin. Myalgia can be severe and disabling, sometimes mimicking fibromyalgia or inflammatory myopathies and leading to extensive diagnostic workup before vitamin D measurement is pursued. Notably, symptom severity does not correlate tightly with 25(OH)D levels, and some patients remain asymptomatic despite significant biochemical deficiency, whereas others experience marked symptoms at higher 25(OH)D concentrations.

Chronic vitamin D deficiency results in osteomalacia, characterized by impaired mineralization of newly formed bone matrix. Patients experience bone pain, particularly in weight-bearing bones (femur, tibia, pelvis) and along the spine, often described as deep aching and exacerbated by physical activity. The pain arises from both structural weakness (unmineralized osteoid accounts for >25% of bone matrix versus normally <5%) and increased bone turnover with microfractures. Unlike osteoporosis, osteomalacia produces radiographically visible changes including loss of sharp corticomedullary distinction, Looser's zones (pseudofractures—radiolucent bands perpendicular to bone cortex, classically at femoral neck, pubic rami, and scapular margins), and a characteristic "rugger jersey spine" pattern in severe cases with alternating sclerotic bands (though this is more typical of renal osteodystrophy).

When 25(OH)D falls below ~15-20 ng/mL, renal calcitriol production becomes insufficient to maintain calcium homeostasis, resulting in symptomatic hypocalcemia. Patients may experience paresthesias (particularly perioral and in fingers/toes), muscle cramps, tetany, or frank seizures in severe cases. Chvostek's sign (twitching of facial muscles when tapping the facial nerve anterior to the ear) and Trousseau's sign (carpopedal spasm upon inflation of a blood pressure cuff above systolic pressure for 3 minutes) represent physical examination findings of neuromuscular irritability due to hypocalcemia. Severe symptomatic hypocalcemia may present with seizures, arrhythmias, or acute decompensation requiring urgent calcium repletion.

VDR is expressed in immune cells including dendritic cells, macrophages, T lymphocytes, and B lymphocytes. Vitamin D deficiency impairs both innate and adaptive immunity through multiple mechanisms: reduced production of antimicrobial peptides (cathelicidin LL-37), impaired Toll-like receptor signaling, shift toward Th2/Th17 response at expense of Th1 and regulatory T cells, and reduced phagocytic capacity. Clinical correlates include increased susceptibility to and severity of respiratory tract infections (tuberculosis, lower respiratory infections, influenza), though the association remains somewhat controversial with conflicting epidemiologic data. Some patients present with recurrent infections as an initial manifestation of vitamin D deficiency.

Nutritional rickets from vitamin D deficiency causes severe skeletal deformities in growing children, particularly in infants and toddlers. The rapid bone turnover in childhood and unopposed PTH stimulation in vitamin D deficiency result in disordered growth plate mineralization and profound skeletal deformities. Classic findings include frontal bossing, delayed closure of anterior fontanelle, expansion of